Another article on Satri Cel, a CART therapy targeting claudin 18.2 on gastric cancer.
just completed enrolment of phase 2 pivotal trial.
CHM CDH17 groundbreaking study has strong parallels to Satie Cel but important differences:
a) CDH17 targets a different protein (CDH17) which is more common than claudin 18.2
b) CDH17 trial is a phase 1/2 such that the company can immediately move to phase 2 (potentially registrational) after proving safe and showing some efficacy in phase 1
https://www.prnewswire.com/news-releases/carsgen-announces-enrollment-completion-in-china-gcgej-pivotal-phase-ii-clinical-trial-of-the-first-in-class-claudin18-2-car-t-satri-cel-302225000.html
- Forums
- ASX - By Stock
- Chimeric: Media Thread
Another article on Satri Cel, a CART therapy targeting claudin...
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
1.4¢ | 1.5¢ | 1.4¢ | $12.73K | 890.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 2014769 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 449172 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 500351 | 0.014 |
12 | 2424769 | 0.013 |
5 | 1066816 | 0.012 |
4 | 697817 | 0.011 |
4 | 485142 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 449172 | 4 |
0.016 | 635854 | 2 |
0.017 | 617827 | 2 |
0.018 | 1788235 | 5 |
0.019 | 987804 | 3 |
Last trade - 15.56pm 26/09/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |